In:
BMC Medical Imaging, Springer Science and Business Media LLC, Vol. 22, No. 1 ( 2022-12)
Abstract:
While 18 F-FDG PET/CT yields valuable prognostic information for patients in first-line therapy of multiple myeloma (MM), its prognostic relevance in relapse is not established. Available studies of relapsed MM describe prognostic thresholds for frequently used PET/CT parameters that are significantly higher than those identified in the first-line setting. The purpose of this study was to evaluate the prognostic role of PET/CT in relapsed MM, based on parameters used in the first-line setting. Methods Our retrospective study included 36 patients with MM who had received autologous or allogeneic stem cell transplantation, suffered at least one relapse, and underwent FDG-PET/CT at relapse. Number of focal bone lesions (FL), maximal standardised uptake value (SUVmax), and presence of PET-positive extramedullary lesions (EMD) were analysed. Results For the number of FLs, the prognostic value was demonstrated with a cut-off of 〉 3 (median OS 3.8 months vs. not reached, p = 0.003). Median OS of patients with SUVmax ≤ 4 was not reached, while it was 3.9 months in patients with SUVmax 〉 4 (p = 0.014). Presence of EMD was a significant prognostic parameter too, with median OS of 3.6 months versus not reached (p = 0.004). The above-mentioned parameters showed prognostic significance for PFS as well. Combination of higher ISS stage and PET/CT parameters identified patients with particularly short OS (3.7 months vs. not reached, p 〈 0.001) and PFS (3.6 vs. 11.7 months p 〈 0.001). Conclusion The PET/CT parameters SUVmax 〉 4, nFL 〉 3, and presence of EMD identify patients with poor prognosis not only in the first-line setting but also in relapsed MM.
Type of Medium:
Online Resource
ISSN:
1471-2342
DOI:
10.1186/s12880-022-00788-4
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2022
detail.hit.zdb_id:
2061975-3
